CatalYm GmbH
Privately held: no public share price · Germany
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | GDF-15Monoclonal antibody | Non-Small Cell Lung CancerBladder Cancer |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
April 2028 (1)
Est. primary completion 2028-04-30 · NCT04725474 · CT.gov ↗
What to watch
2029 (4)
March 2029 (1)
Est. primary completion 2029-03-31 · NCT07098988 · CT.gov ↗
What to watch
September 2029 (1)
VisugromabPhase 2Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma …
Est. primary completion 2029-09 · NCT07219459 · CT.gov ↗
What to watch
October 2029 (1)
Est. primary completion 2029-10-01 · NCT07246863 · CT.gov ↗
What to watch
December 2029 (1)
Est. primary completion 2029-12 · NCT07112196 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.